A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT).

MLA

Bubalo, Joseph, et al. “A Randomized, Placebo-Controlled Pilot Trial of Aprepitant Combined with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Cyclophosphamide-Based Conditioning Regimens Prior to Hematopoietic Stem Cell Transplant (HSCT).” Bone Marrow Transplantation, vol. 53, no. 8, Aug. 2018, pp. 1010–18. EBSCOhost, https://doi.org/10.1038/s41409-018-0106-8.

APA

Bubalo, J., Mulverhill, K., Meyers, G., Hayes-Lattin, B., & Maziarz, R. (2018). A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bone Marrow Transplantation, 53(8), 1010–1018. https://doi.org/10.1038/s41409-018-0106-8

Chicago

Bubalo, Joseph, Kelsey Mulverhill, Gabrielle Meyers, Brandon Hayes-Lattin, and Richard Maziarz. 2018. “A Randomized, Placebo-Controlled Pilot Trial of Aprepitant Combined with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Cyclophosphamide-Based Conditioning Regimens Prior to Hematopoietic Stem Cell Transplant (HSCT).” Bone Marrow Transplantation 53 (8): 1010–18. doi:10.1038/s41409-018-0106-8.